Quetiapine in Co-Morbid Depressive and Anxiety Disorders

Sponsor

Centre for Addiction and Mental Health (Other)

Overall Status

Completed

CT.gov ID

NCT00688818

Collaborator

(none)

108

Enrollment

Locations

Arms

Duration (Months)

Patients Per Site

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This multi-centred study will be conducted at three centres. The design will be a randomized, placebo-controlled, parallel-group one. This investigation will evaluate the efficacy of add-on Quetiapine XR (extended release) treatment for patients who meet diagnostic criteria for depressive disorders and one or more comorbid anxiety disorder.

Condition or Disease	Intervention/Treatment	Phase
Major Depressive Disorder Dysthymic Disorder Anxiety Disorders Generalized Anxiety Disorder Social Anxiety Disorder Panic Disorder Post-traumatic Stress Disorder	Drug: Quetiapine Drug: Placebo	N/A

Detailed Description

The primary objective is to examine the beneficial effect of quetiapine augmentation of first-line antidepressants in refractory depression with co-morbid anxiety, compared to placebo. It is hypothesized that significant improvement on depression and anxiety symptoms will be seen as evidenced by reduction in Hamilton Depression Rating Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA) scores after the 12 week treatment period for those who received Quetiapine XR augmentation compared to those who received placebo.2.2

Secondary objectives: 1) To establish the tolerability and safety of Quetiapine XR versus Placebo in patients with co-morbid depressive and anxiety disorders;2) To assess and compare the efficacy of Quetiapine XR versus Placebo improving quality of life in patients with co-morbid depressive and anxiety disorders.; 3) To assess and compare the efficacy of Quetiapine XR versus Placebo on clinical measures symptoms associated to co-morbid depressive and anxiety disorders.

Study Design

Study Type:

Interventional

Actual Enrollment :

108 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Randomized, Placebo-Controlled Effectiveness Study of Quetiapine XR in Co-Morbid Depressive and Anxiety Disorders

Study Start Date :

Jun 1, 2008

Actual Primary Completion Date :

Jun 1, 2013

Actual Study Completion Date :

Jun 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Quetiapine and existing psychotropics	Drug: Quetiapine Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period. Other Names: Seroquel
Placebo Comparator: Placebo and existing psychotropics	Drug: Placebo Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.

Arm

Intervention/Treatment

Experimental: Quetiapine and existing psychotropics

Drug: Quetiapine

Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.

Other Names:

Seroquel

Placebo Comparator: Placebo and existing psychotropics

Drug: Placebo

Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.

Outcome Measures

Primary Outcome Measures

Hamilton Depression Rating Scale (HAMD-17) [12 weeks]

Secondary Outcome Measures

Hamilton Anxiety Scale [Baseline, 6 weeks and 12 weeks]
Quality of Life Enjoyment and Satisfaction Scale [Baseline, 6 weeks and 12 weeks]
Penn State Worry Questionnaire [Baseline, 6 weeks and 12 weeks]
Panic Disorder Severity Scale [Baseline, 6 weeks and 12 weeks]
Leibowitz Social Anxiety Scale [Baseline, 6 weeks and 12 weeks]
Post-traumatic Diagnostic Scale [Baseline, 6 weeks and 12 weeks]
Clinical Global Impression Scale [Baseline, 6 weeks and 12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Provision of written informed consent
Male and female patients must be of 18 to 65 years of age.
Women of childbearing potential must have a negative pregnancy test and must, in the investigator's opinion, practice a clinically accepted, reliable method of contraception during this study.
A diagnosis of Major Depressive Disorder or Dysthymic Disorder as defined by DSM-IV criteria and failed to respond to at least one first line treatment. The patient must be receiving antidepressant treatment (SSRIs, SNRIs or mirtazapine).
A co-morbid diagnosis of one or more of the following: Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, and Post Traumatic Stress Disorder, and Obsessive-Compulsive Disorder, as defined by DSM-IV criteria
A minimum score of ≥17 at Baseline on the 17-item HAM-D.
Able to understand and comply with the requirements of the study

Exclusion Criteria:

The presence or history of Psychotic Disorders, Bipolar Disorders, Mood Disorders with Psychotic Features
Patients who, in the investigator's judgment, would require treatment with additional psychotherapeutic drugs, electroconvulsive therapy (ECT), or intensive psychotherapy during the course of the study.
ECT within the preceding 6 months of screening before inclusion.
Regular, formal psychotherapy (excluding supportive therapy) started within the last 3 months before inclusion.
Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
Known intolerance or lack of response to quetiapine fumarate.
Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment
Use of any of the following significant cytochrome P450 inducers in the 14 days preceding enrolment
Patients who are currently receiving: monoamine oxidase inhibitors, tricyclic antidepressants, oral neuroleptics, or type 1C anti-arrhythmics within two weeks of screening; herbal psychoactive treatments (St. John's Wort, Kava Kava, Gingko Biloba) within two weeks of screening.
Patients taking SSRIs or SNRIs for less than two weeks or at a less than therapeutic dose prior to enrolment.
Patients who require concurrent psychotropic medication other than allowed medication specified in protocol.
Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation.
Patients who have met DSM-IV criteria for abuse of or dependence on any drug, including alcohol within 3 months prior to screening.
Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment
Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator
Patients with clinically significant abnormalities in hematology, clinical chemistry, urinalysis or ECG at the screening visit.
Involvement in the planning and conduct of the study
Previous enrolment or randomisation of treatment in the present study.
Participation in another drug trial within 4 weeks prior enrolment into this study or longer in accordance with local requirements
A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:a)Unstable DM (HbA1c) >8.5%, b) hospital admission for DM or DM related illness in past 12 weeks, c)not under physician care for DM, d) physician responsible for patient's DM care has not approved patient's participation in the study,or indicated DM is controlled e)change in dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to randomisation. For thiazolidinediones (glitazones) this period will not be less than 8 weeks, g)taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks (Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study)
An absolute neutrophil count (ANC) of <= 1.5 x 10^9 per

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Chatham-Kent Health Alliance	Chatham	Ontario	Canada	N7L1B7
2	Centre for Neuropsychiatric Study	Markham	Ontario	Canada	L6B 1A1
3	Credit Valley Medical Arts Centre	Mississauga	Ontario	Canada	L5M 4N4
4	Centre for Addiction and Mental Health	Toronto	Ontario	Canada	M5T 1R8